8-K
filed June 27, 2024, 7:59 PM ET
ticker CLYM
CIK 0001768446
M&A
confidence high
sentiment neutral
materiality 0.85
Climb Bio, Inc. (CLYM): M&A transaction — Eliem closes acquisition of Tenet Medicines, gains TNT119 autoimmune drug, raises $120M PIPE
Climb Bio, Inc.
- Acquisition of Tenet closed June 27; 5,560,047 Eliem shares issued to Tenet equityholders.
- PIPE of 31,238,282 shares raised ~$120M gross; proceeds to fund TNT119 development.
- Lead asset TNT119 (budoprutug) licensed from Acelyrin; up to $157.5M in milestone payments plus royalties.
- New CEO Aoife Brennan appointed effective close; Stephen Thomas joins board and as consultant.
- Tenet also assumed CRH license with up to £106.8M milestones and ProBioGen cell line agreement.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Stephen Thomas was elected as Director at Climb Bio, Inc..
- Action
- elected
- Role
- Director
Exact text from the filing
the Board elected Stephen Thomas, Ph.D., the then-Chief Executive Officer of Tenet, to serve as a director on the Board, subject to and contingent and effective upon the closing of the Acquisition, from the Effective Date until the Company’s 2025 annual meeting of stockholders and thereafter until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Aoife Brennan was elected as Director at Climb Bio, Inc..
- Action
- elected
- Role
- Director
Exact text from the filing
In addition, Dr. Brennan was elected as a director to serve on the Board from the Effective Date until the Company’s 2027 annual meeting of stockholders and thereafter until her successor has been duly elected and qualified or until her earlier death, resignation or removal.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Aoife Brennan was appointed as President and Chief Executive Officer at Climb Bio, Inc..
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
the Company’s Board of Directors (the “Board”) appointed Aoife Brennan, M.B., Ch.B., as President and Chief Executive Officer of the Company, effective upon the closing of the Acquisition (the “Effective Date”).
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Climb Bio, Inc. completed an acquisition involving Tenet Medicines, Inc. (closed 2024-06-27).
- Action
- acquisition
- Counterparty
- Tenet Medicines, Inc.
- Closing
- 2024-06-27
Exact text from the filing
On June 27, 2024, the Company completed its acquisition of Tenet in accordance with the terms of the Acquisition Agreement.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.